Physician profile
Kyrieckos Aleck
NPI 1891767307
$429,218.10
in general payments reported to CMS, 2019-2025
12 companies · $43K in 2025
The $43K reported for 2025 was more than what 93% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62K · 2020: $45K · 2021: $27K · 2022: $47K · 2023: $86K · 2024: $120K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $212K · Travel and Lodging: $31K · Food and Beverage: $4,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $212,432.75 |
| Travel and Lodging | $31,489.71 |
| Food and Beverage | $4,751.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $279,958.41 | 2019-2025 | |
| Ultragenyx Pharmaceutical INC. | $67,532.27 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33,731.01 | 2020-2025 | Elaprase, Vpriv |
| Alexion Pharmaceuticals, INC. | $16,734.74 | 2019-2021 | |
| Shire North American Group INC | $12,931.07 | 2019 | |
| Kyowa Kirin, INC. | $11,856.92 | 2023-2024 | Crysvita |
| Amicus Therapeutics, INC. | $4,003.34 | 2019-2020 | |
| Chiesi USA, INC. | $2,144.26 | 2020-2021 | |
| Biomarin Pharmaceutical INC. | $198.75 | 2019-2021 | |
| Travere Therapeutics, INC. | $95.91 | 2019-2021 | |
| Spark Therapeutics, INC. | $17.17 | 2021 | |
| Pfizer INC. | $14.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyrieckos Aleck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.